Clinical Trials Using PI3K Inhibitor GDC-0084
Clinical trials are research studies that involve people. The clinical trials on this list are studying PI3K Inhibitor GDC-0084. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Genetic Testing in Guiding Treatment for Patients with Brain Metastases
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, GDC-0084, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.
Location: 355 locations
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II / III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Location: 28 locations
GDC-0084 and Radiation Therapy for the Treatment of Solid Tumor Brain Metastases or Leptomeningeal Metastases with PI3K Pathway Mutations
This phase I trial studies the side effects of GDC-0084 and radiation therapy to the brain in treating patients with PI3K pathway-mutated solid tumors that have spread to the brain and / or membranes lining the brain and spinal cord (brain and / or leptomeninges metastases). When a cancer has a PI3K pathway mutation, it sends signals to other cells in the body to encourage rapid growth, leading to the spread of cancer. PI3K mutations are common in many types of cancer, and they cause radiation therapy to be less effective. GDC-0084 reduces the activity of PI3K-related signaling. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving GDC-0084 with whole or partial brain radiation therapy may be an effective treatment for solid tumors brain metastases or leptomeningeal metastases.
Location: 7 locations
Paxalisib and Trastuzumab in Treating Patients with HER2 Positive Breast Cancer Brain Metastases
This phase II trial studies how well paxalisib in combination with trastuzumab works in treating patients with HER2 positive breast cancer that has spread to the brain (brain metastases). Paxalisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab is a form of “targeted therapy” because it works by attaching itself to specific molecules (receptors) on the surface of breast cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by body’s immune system. It is not yet known how a HER2-positive breast cancer that has spread to the brain responds to combination of paxalisib and trastuzumab.
Location: 2 locations